Results 1 to 10 of about 27,618 (191)

Ataxin-2-like promotes translation of nonpolyadenylated reovirus mRNA [PDF]

open access: yesNature Communications
Mammalian orthoreovirus (reovirus) nonstructural protein μNS nucleates viral factories (VFs), which are sites of viral genome replication, protein synthesis, and particle assembly.
Xayathed Somoulay   +10 more
doaj   +2 more sources

Modulating autophagy in KRAS mutant colorectal cancer using combination of oncolytic reovirus and carbamazepine. [PDF]

open access: yesPLoS ONE
Oncolytic reovirus is a potential therapeutic for colorectal cancer patients with a mutant KRAS gene. Reovirus hijacks the autophagic machinery and preferentially induces apoptosis in patients with a KRAS mutation.
Aaron Shaykevich   +4 more
doaj   +2 more sources

Annexin A2 stabilizes the endoplasmic reticulum and actin cytoskeleton and influences the formation of reovirus factories [PDF]

open access: yesJournal of Virology
Early in infection, mammalian orthoreoviruses (reoviruses) build neo-organelles called viral factories (VFs). These structures incorporate fragments of endoplasmic reticulum (ER) and serve as sites of viral genome replication and particle assembly.
Raquel Tenorio   +10 more
doaj   +2 more sources

Paired immunoglobulin-like receptor B is an entry receptor for mammalian orthoreovirus

open access: yesNature Communications, 2023
Mammalian orthoreovirus (reovirus) infects most mammals and is associated with celiac disease in humans. In mice, reovirus infects the intestine and disseminates systemically to cause serotype-specific patterns of disease in the brain.
Pengcheng Shang   +14 more
doaj   +1 more source

Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy

open access: yesJournal for ImmunoTherapy of Cancer, 2022
Background Many solid tumors do not respond to immunotherapy due to their immunologically cold tumor microenvironment (TME). We and others found that oncolytic viruses (OVs), including reovirus type 3 Dearing, can enhance the efficacy of immunotherapy by
Rob C Hoeben   +11 more
doaj   +1 more source

Activation of p53 by chemotherapeutic agents enhances reovirus oncolysis. [PDF]

open access: yesPLoS ONE, 2013
Mammalian reovirus is a benign virus that possesses the natural ability to preferentially infect and kill cancer cells (reovirus oncolysis). Reovirus exploits aberrant Ras signalling in many human cancers to promote its own replication and spread.
Da Pan   +6 more
doaj   +1 more source

Oncolytic reovirus in canine mast cell tumor. [PDF]

open access: yesPLoS ONE, 2013
The usage of reovirus has reached phase II and III clinical trials in human cancers. However, this is the first study to report the oncolytic effects of reovirus in veterinary oncology, focusing on canine mast cell tumor (MCT), the most common cutaneous ...
Chung Chew Hwang   +11 more
doaj   +1 more source

Reovirus Low-Density Particles Package Cellular RNA

open access: yesViruses, 2021
Packaging of segmented, double-stranded RNA viral genomes requires coordination of viral proteins and RNA segments. For mammalian orthoreovirus (reovirus), evidence suggests either all ten or zero viral RNA segments are simultaneously packaged in a ...
Timothy W. Thoner   +3 more
doaj   +1 more source

Reovirus infection of tumor cells reduces the expression of NKG2D ligands, leading to impaired NK-cell cytotoxicity and functionality

open access: yesFrontiers in Immunology, 2023
In recent years, reoviruses have been of major interest in immunotherapy because of their oncolytic properties. Preclinical and clinical trials, in which reovirus was used for the treatment of melanoma and glioblastoma, have paved the way for future ...
Raghad Khaleafi   +6 more
doaj   +1 more source

Modulation of Reoviral Cytolysis (I): Combination Therapeutics

open access: yesViruses, 2023
Patients with stage IV gastric cancer suffer from dismal outcomes, a challenge especially in many Asian populations and for which new therapeutic options are needed.
Yoshinori Mori   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy